A DIAGNOSTIC BLOOD TEST METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE

Abstract

The present invention relates to a method for diagnosing neurodegenerative processes in the CNS, such as Alzheimer's disease, by measuring syndecan-3 expression from monocytes isolated from the systemic circulation with antibodies and ligands specific to any portion of the 442 amino acid long protein core of syndecan-3.

Claims

1. Method for diagnosing central nervous system (CNS) neurodegenerative diseases, such as Alzheimer's disease, characterized by measuring the syndecan-3 expression of monocytes isolated from the systemic circulation with an antibody or any other ligand specific to the 442 amino add protein core of syndecan-3 and evaluating the deviation from the healthy controls.

2. The method of claim 1, characterized by, that the antibody or ligand specific to any portion of the 442 amino acid long protein core of syndecan-3, is present in soluble form or bound to a surface.

Description

[0006] We aimed to investigate syndecan-3 expressed on monocytes as a prognostic biomarker in neurodegenerative diseases such as Alzheimer's.

[0007] Our experiments examined changes in syndecan-3 levels in circulating monocytes in an APPSWE-Tau mouse model of Alzheimer's disease. Syndecan-3 levels of circulating monocytes were examined in blood samples from APPSWE-Tau (Taconic Biosciences) and healthy C57BL/6 mice with a minimum age of 6 months. The number of animals in the healthy control and APPSWE-Tau groups was 10-10, with an equal number of males (5-5 individuals) and females (5-5 individuals) in both groups. Blood of mice anesthetized with Avertin was collected with cardiac puncture. After transcardinal perfusion with ice-cold PBS (2 mL/min, 8 min), the brain was removed, cut in half frontally, and frozen in dry ice for further microscopic examinations. Blood-derived monocytes were isolated with the EasySep™ Mouse Monocyte Isolation Kit (Stemcell Technologies, cat no. 19861), while brain samples were stained for Alzheimer's disease plaques to check the severity of the brain lesion in the animals. Assessment of cell surface syndecan-3 expression and syndecan-3 content of monocytes showed that both cell surface syndecan-3 expression and syndecan-3 content of monocytes isolated from diseased mice were significantly (p<0.05) higher than those of healthy controls (FIGS. 1A-D). (Cell surface syndecan-3 expression of monocytes were measured with an AMNIS FlowSight flow cytometer using APC-labeled human syndecan-3 antibody [R&D Systems, Catalog No. FAB3539A], while syndecan-3 content of whole monocyte lysates was measured with a mouse syndecan-3 ELISA kit (PicoKine™, Baster Biological Technology, Pleasanton CA, USA, cat. no. EK1556; absorbance was measured with a BioTek Cytation 3 Cell Imaging Multi-Mode Reader). For each flow cytometric measurement, the expression of 10,000 monocytes of syndecan-3 was examined. After perfusion, the brains were isolated, frontally cut and fixed in 4% paraformaldehyde for 18 h. Then 30 μm thick sagittal sections were cut and Aβ plaques were stained with Aβ specific antibody (MOAB-2. NOVUS Biologicals, cat. number NBP2-13075) and 488-labeled secondary antibody (ThermoFischer Scientific, cat. no. A-21141) The number and size of Aβ plaques deposition in the resulting brain sections were assessed with a BioTek Cytation 3 Cell Imaging Multi-Mode Reader (FIG. 1E).

[0008] Syndecan-3 levels of monocytes isolated from the blood correlated with the extents of plaque deposition in the brains of APPSWE-Tau mice: i.e., Aβ plaque deposition in the central nervous system was associated with high syndecan-3 expression by blood monocytes (the value of Pearson's correlation coefficient [r] between CNS plaque deposition and syndecan-3 expression of monocyte is 0.93—see FIG. 2.)

[0009] The present invention is based on the surprising finding that the level of syndecan-3 in circulating monocytes in Alzheimer's disease is significantly increased, such that the level of syndecan-3 in monocytes isolated from blood correlates with CNS plaque deposition.

[0010] The present invention relates to a method for diagnosing CNS neurodegenerative diseases, such as Alzheimer's disease, by measuring the syndecan-3 expression of monocytes isolated from the systemic circulation with an antibody or any other ligand specific to the 442 amino add protein core of syndecan-3 and the deviation from the healthy controls is evaluated.

[0011] Specific antibodies or ligands are known to those skilled in the art, for example, from the following literature Hudák, Kusz, Domonkos et al. 2019 (Sci Rep 9, 16543).

[0012] The specificity of the method is ensured by the specific binding of the antibody or ligand to any part of the 442 amino acid long core protein of syndecan-3.

[0013] Syn decan-3-specific antibody or ligand alone or attached to a surface binds to syndecan-3 expressed on monocytes, so it can be used as a diagnostic method in neurodegenerative diseases.

[0014] The syndecan-3 specific antibody or ligand can be contacted with blood monocytes alone or in conjunction with a fluorescent or other optical signaling agent.

[0015] As a control value, the following mean value (t SEM) were measured with a BioTek Cytation 3 Cell Imaging Multi-Mode Reader. 54.70 pg (±12.96) syndecan-3/mL, while measuring the syndecan-3 expression of monocytes isolated from healthy controls with Amnis® FlawSight® Imaging Flow Cytometer, the following fluorescence mean value (±SEM) was obtained: 7546.71±1329.47 arbitary unit (a.u.)/cell

[0016] The data is for information only and depends on the measurement techniques, so the scope of the invention is not limited to the arbitary values given here.